Exenatide Dosing & Reconstitution Guide
Dosing Protocol
Route: Subcutaneous injection Frequency: Twice daily (Byetta) or Once weekly (Bydureon) Dose Range: Byetta: 5-10 mcg BID; Bydureon: 2 mg once weekly Cycle Length: Ongoing as prescribed Timing: Byetta: within 60 minutes before morning and evening meals, at least 6 hours apart. Bydureon: any time of day, with or without meals, same day each week.
Titration Schedule
Weeks 1-4 (Byetta): 5 mcg twice daily, within 60 min before meals Week 5+ (Byetta): 10 mcg twice daily Week 1+ (Bydureon): 2 mg once weekly (no titration needed)
Timeline & Pharmacokinetics
Onset: 1-2 hours (Byetta) Peak Plasma: 2.1 hours (Byetta) Half-Life: 2.4 hours (Byetta); ~2 weeks sustained release (Bydureon) Steady State: 6-7 weeks (Bydureon) Time to Results: 4-8 weeks for glycemic improvement Washout: 2-3 days (Byetta); 10+ weeks (Bydureon)
Storage
Lyophilized: Refrigerate at 2-8 °C (36-46 °F) before first use Reconstituted: Byetta pen: refrigerate, use within 30 days after first use; Bydureon: use immediately after reconstitution Shelf Life: 30 days
Injection Sites
Abdomen, Thighs, Upper arms
Safety & Contraindications
Safety: Common (>=5%): nausea (44% with Byetta, decreases over time), vomiting, diarrhea, dizziness, headache, jitteriness Injection site reactions more common with Bydureon extended-release (up to 17%) including nodules at injection site Hypoglycemia risk increased when combined with sulfonylureas or insulin
Contraindications: Personal or family history of medullary thyroid carcinoma (FDA black box warning for Bydureon); Multiple endocrine neoplasia syndrome type 2 (MEN2); Severe renal impairment (eGFR <30 mL/min) or end-stage renal disease